Purchase this article with an account.
Jiro Kogo, Akira Shiono, Hiroyuki Takeda, Satoki Ueno, Hitoshi Takagi; Clinical and Morphologic Changes in Patients with Polypoidal Choroidal Vasculopathy 6 Months After Ranibizumab Monotherapy. Invest. Ophthalmol. Vis. Sci. 2012;53(14):4398.
Download citation file:
© ARVO (1962-2015); The Authors (2016-present)
To evaluate the clinical and morphological changes in eyes with polypoidal choroidal vasculopathy (PCV) 6 months after ranibizumab monotherapy.
Twenty-two patients (twenty three eyes) with PCV who had been untreated previously were underwent intravitreal injection of 0.5 mg ranibizumab monthly for 3 months followed by a PRN reinjection methods. All patients were followed using spectral-domain optical coherence tomography (SD-OCT), fluorescein and indocyanine green angiographies (FA and ICGA). Best-corrected logMAR visual acuity (BCVA), central foveal thickness (CFT), the number of polyp, the largest polyp size and the greatest linear dimension (GLD) were compared among baseline and 6 months after the primary injection. Multiple regression analysis using preoperative parameters was performed to identify factors significantly related to visual outcome.
BCVA significantly improved from 0.45 to 0.27 (p < .001). CFT significantly decreased from 420 to 290μm (p = .0019). The mean number of injections for 6 months was 3.5 ± 0.7. The baseline ICGA images showed polyps in all eyes and abnormal vacular network (AVN) in 19 (83%) eyes. ICGA showed the polyps complete resolved in 7 (30%) eyes, partial resolved in 7 (30%) eyes and 4 new polyps 6 months after the primary injection. However, the AVN remained in all eyes. GLD changed from 3267 ± 1,455 to 3355 ± 1207 μm. Multiple regression analysis showed that preoperative BCVA yielded the highest correlation coefficient with postoperative BCVA (p < .00001).
Ranibizumab monotherapy improves VA in eyes with PCV. Although polyps tended to improve, AVN remained in all eyes. And preoperative BCVA is strongly correlated with visual outcome after the primary injection.
This PDF is available to Subscribers Only